Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCsPeng Xu, De‐Pei Liu, Xiuzhen Liu et al.|Scientific Reports|2015Cited by 148